| Literature DB >> 33506341 |
Lin Zhu1, Jiajun Ling1, Zhi Zhu1, Tian Tian2, Yanling Song3, Chaoyong Yang4.
Abstract
Infectious diseases caused by pathogenic microorganisms such as viruses and bacteria pose a great threat to human health. Although a significant progress has been obtained in the diagnosis and prevention of infectious diseases, it still remains challenging to develop rapid and cost-effective detection approaches and overcome the side effects of therapeutic agents and pathogen resistance. Functional nucleic acids (FNAs), especially the most widely used aptamers and DNAzymes, hold the advantages of high stability and flexible design, which make them ideal molecular recognition tools for bacteria and viruses, as well as potential therapeutic drugs for infectious diseases. This review summarizes important advances in the selection and detection of bacterial- and virus-associated FNAs, along with their potential prevention ability of infectious disease in recent years. Finally, the challenges and future development directions are concluded.Entities:
Keywords: Functional nucleic acids; Infectious disease; Selection
Mesh:
Substances:
Year: 2021 PMID: 33506341 PMCID: PMC7840224 DOI: 10.1007/s00216-020-03124-3
Source DB: PubMed Journal: Anal Bioanal Chem ISSN: 1618-2642 Impact factor: 4.478
Fig. 1The structures of typical aptamers and DNAzymes. a CoV2-RBD-4C aptamer against the receptor-binding domain of the SARS-CoV-2 Spike glycoprotein [2]. b The RNA-cleaving DNAzyme VEA-2 [3]. c The peroxidase DNAzyme PS2.M [4]
Scheme 1Functional nucleic acids for infectious disease detection and prevention
A summary of aptamers selected for the detection of bacteria, since 2000 until today
| Target type | Aptamer name | Target | Aptamer type | Sequence of the aptamer (5′ to 3′) | Ref. | |
|---|---|---|---|---|---|---|
| Bacteria | VPCA-apta #1 | DNA | CATACCAAGGCTACCGAGGTTCCAGATATTGGCCGCTATG | 2.04 ± 0.12 | [ | |
| AM-6 | DNA | CGTGATGATGTTGAGTTGGGGTGATGGGTGCATGTGATGAAAGGGGTTCGTGCTATGCTGTTTTGTCTAATAATACTAGTCCTTGCCAAGGTTTATTCCAGTAATGCCAACCAATCT | 0.1076 ± 0.0678 | [ | ||
| Vapt2 | DNA | TTCTGATGAGAGTTGCGACCTCCCGGATGAGTGCCCTGGCTCCGGGTTTGTCTATTTTTGGGGGTGTTGACAGATATCCT | 26.8 ± 5.3 | [ | ||
| Clone 63 | DNA | GCCTGTTGTGAGCCTCCTAACAGGAGGCGAACGGGCAGGTTCTTGGGGAGACAAGAATAAGCATGCTTATTCTTGTCTCC | 0.0284649 ± 0.00434 | [ | ||
| E-CA 20 | DNA | CACACACGGAACCCCGACAACATACATACGGTGAGGGTGG | 7 | [ | ||
| BB16-11f | DNA | CTCCCAGGCCGTTGGGGCGTTGCCTGCGT | 18.66 ± 1.41 | [ | ||
| VA2 | DNA | GACGCTTACTCAGGTGTGACTCGTCGGTCGGGTGGTTGGGGTGGGTGGTCGGTTTTTAAGCTGTGTCATTGTCCGAAGGACGCAGATGAAGTCTC | 14.31 ± 4.26 | [ | ||
| Lyd-3 | DNA | TGACGAGCCCAAGTTACCTGCCCCCGAACCATACCACACGATGCCCCGTACCCCAGCCACCAGAATCTCCGCTGCCTACA | 661.8 ± 111.3 | [ | ||
| VFCA-02 | DNA | GGGCATGTGGACTTGCGATTTCGGTTTGGTGTGGTTGGGG | 12.8 | [ | ||
| Apt-5 | DNA | TGAGCCCAAGCCCTGGTATGCGGATAACGAGGTATTCACGACTGGTCGTCAGGTATGGTTGGCAGGTCTACTTTGGGATC | 9.04 ± 2.80 | [ | ||
| RAB35 | DNA | TAGCTCACTCATTAGGCACGGGGGGTTGTGCCATTTAAGATGACCGGTTGCCGCGATTTGCATAGTTAAGCCAGCC | 34 ± 5 | [ | ||
| Apt-2 | DNA | ATAAGCATGAATTGACCAACCTAAACTTATTCATTTTCCAGCACCTCTAATATTACTGGC | 10.3 ± 2.5 | [ | ||
| Biomarker of bacteria | C7 | SEA protein | DNA | CCTAACCGATATCACACTCACAGTATACCGCTCCACCAGTGTGATATCGGGATCTGCTGACGTTGGTCGT CATTGGAGTATC | 7.44 ± 0.6 | [ |
| EA7 | Lipid A region of LPS | DNA | ATAGGAGTCACGACGACCAGCCTTCTAACAGAATGTTGTTAGATAGCTTTGAAGCTGGTCTATGTGCGTCTACCTCTTGA | 102 ± 17 | [ | |
| ML12 | LF protein | DNA | CGAGGGAGACGCGAACCTTCTCGCCTTGGG- | 11.0 ± 2.7 |
A summary of aptamers selected for the detection of virus, since 2000 until today
| Target type | Aptamer name | Target | Aptamer type | Sequence of the aptamer (5′ to 3′) | Ref | |
|---|---|---|---|---|---|---|
| Virus | No. 11 | BVDV type 1 | DNA | CGTACGGAATTCGCTAGCTGCGCATCCACAAATGTATTGTCGGGGGATGGATCCGAGCTCCACGTG | 4.08 × 104TCID50/mL | [ |
| IF4 | Avian influenza | DNA | GGTCGACGCTAGCCCCAGGCGGTGCGAGCTACTGCCATTGCACCACGTGGAGCTCGGATCC | 3 × 104EID50/mL | [ | |
| PF1 | HIV RT | DNA | AGGAAGGCTTTAGGTCTGAGATCTCGGAAT | 82 ± 7 nM | [ | |
| A20S | H1N1 | DNA | GGACCAGTTGTCTTTCGGTCTCTACCCCAGCCCGT | 5.56 ± 4.14 nM | [ | |
| H01 | HbsAg | DNA | GGGAATTCGAGCTCGGTACCCACAGCGAACAGCGGCGGACATAATAGTGCTTACTACGACCTGCAGCTGCAGGCATGCAAGCTTGG | - | [ | |
| Biomarker of virus | - | Norovirus capsid protein VP1 | DNA | GTCTGTAGTAGGGAGGATGGTCCGGGGCC CCGAGACGACGTTATCAGGC | - | [ |
| A10 | HA1 proteins of H5N1 | DNA | GAATTCAGTCGGACAGCGGGGTTCCCATGCGGATGTTATAAAGCAGTCGCTTATAAGGGATGGACGAATATCGTCTCCC | - | [ | |
| Aptamer 1 | SARS-CoV nucleocapsid protein | DNA | GCAATGGTACGGTACTTCCGGATGCGGAAACTGGCTAATTGGTGAGGCTGGGGCGGTCGTGCAGCAAAAGTGCACGCTACTTTGCTAA | 4.93 ± 0.30 nM | [ | |
| C4 | HCV core protein | DNA | GCACGCCAGACCAGCCGTCCTCTCTTCATCCGAGCCTTCACC GAGC | - | [ | |
| 45-mer | Mtase of DENV | RNA | GGUUGGGCACAUAUAGACUGUGUAAUUCGUAUAGUGUGCAUAACC | 15.6 nM | [ | |
| Aptamer 1 | SARS-CoV N protein | RNA | GGGAGAGCGGAAGCGUGCUGGGCCUGUCGUUCGCUGUCUUGCUACGUUACGUUACACGGUUGG CAUAACCCAGAGGUCGAUGGAUCCCCCC | 1.65 nM | [ | |
| Sc5c3 | HPV16 | RNA | GGGAACAAGCUGCACAGGUUACCCCCGCUUGGGUCUCCCUAUAGUGAGUCGUAUUA | 0.05 pM | [ | |
| Aptamer B.2 | HCV | RNA | CGAAGCCGCUAUGGACCAGUGGCGCGGCUUCGGCCCGACGGAGUG | 1.5 ± 0.2 nM | [ | |
| C7-35M | Hemagglutinin protein of AIV | RNA | ATTAACCCTCACTAAAGGGAGGTAGTTATAGTATATGGAAGGGGGTGTCGTATGGTCGAATAAGTTAACG | - | [ | |
| CoV2-RBD-1C | SARS-CoV-2 RBD | DNA | CAGCACCGACCTTGTGCTTTGGGAGTGCTGGTCCAAGGGCGTTAATGGACA | 5.8 ± 0.8 nM | [ | |
| DNA | ATCCAGAGTGACGCAGCATTTCATCGGGTCCAAAAGGGGCTGCTCGGGATTGCGGATATGGACACGT | 19.9 ± 2.6 nM | [ |
Fig. 2Schematic of a the electrochemical detection for H37Rv by the Au-IED MSPQC system [63], b a SERS platform for the detection of S. aureus [64], c a SERS platform for the multiplex analysis of S. aureus and E. coli [65], and d a fluorescence strategy for the detection of Staphylococcus aureus (S. aureus) [66]
Fig. 3Schematic of a H5N1 viral protein detection by the enzymatic reaction [85], b the cognate pair of the lateral flow strip detecting H5N2 [86], c SPR aptasensor for the detection of AI H5N1 virus [87], and d aptamers specifically binding different E2 proteins on HCV [88]
Fig. 4Bacterial biosensors engineered with DNAzymes. a Visual detection of bacteria [116]. b The fluorescence-based detection method [117]. c The surface plasmon resonance (LSPR) sensing strategy to detect E. coli [118]. d The DNAzyme feedback amplification (DFA) strategy [119]
Fig. 5DNAzyme-based biosensors for the detection of virus. a Visual detection of virus [129]. b, c Fluorescence-based biosensors for the detection of virus [130, 131]. d Electrochemical methods for virus detection [132, 133]